docetaxel anhydrous has been researched along with Lymphoma, Non-Hodgkin in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chia, VM; Langeberg, WJ; Morrow, PK; Page, JH; Siozon, CC | 1 |
| Brunello, A; Extermann, M; Kapoor, R | 1 |
| Cooke, LS; Fisher, RI; Mahadevan, D; Manziello, A; Miller, TP; Morales, C; Persky, DO; Qi, W; Stejskal, A | 1 |
| Davies, JM; Hancock, BW; Hough, RE; Lorigan, PC; Molife, R; Zekri, JM | 1 |
| Barcos, M; Budman, DR; Cooper, MR; Johnson, JL; Peterson, BA; Petroni, GR; Schlossman, DM | 1 |
| Ohnishi, K; Ohno, R | 1 |
| Armand, JP; Couteau, C | 1 |
| Lyerly, HK; Morse, MA; Vredenburgh, JJ | 1 |
| Alexopoulou, A; Deutsch, M; Dourakis, SP; Sevastianos, VA; Stavrianeas, N | 1 |
2 review(s) available for docetaxel anhydrous and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
[New antitumor drugs for non-Hodgkin's lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Prednisone; Rituximab; Taxoids; Vincristine | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
2 trial(s) available for docetaxel anhydrous and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Blood Cell Count; Disease-Free Survival; Docetaxel; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2003 |
Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 1997 |
5 other study(ies) available for docetaxel anhydrous and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infection Control; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Risk Factors; Rituximab; Taxoids; Vincristine; Young Adult | 2014 |
Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Florida; Humans; Hyperglycemia; Kaplan-Meier Estimate; Linear Models; Lymphoma, Non-Hodgkin; Male; Medical Records; Middle Aged; Neoplasm Staging; Prednisone; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Rituximab; Taxoids; Treatment Outcome; Vincristine | 2011 |
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antigens, Nuclear; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Azepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Cyclin D1; Docetaxel; Gene Expression Profiling; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rituximab; Spindle Apparatus; Taxoids; Vincristine; Xenograft Model Antitumor Assays | 2012 |
A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cells, Cultured; Culture Media, Serum-Free; Cyclophosphamide; Dendritic Cells; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-4; Leukapheresis; Leukocyte Count; Lymphocyte Culture Test, Mixed; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neutropenia; Paclitaxel; Taxoids | 1999 |
Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Eruptions; Female; Humans; Lymphoma, Non-Hodgkin; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome | 2002 |